Studies have shown that the activation of Nrf2 and induction of HO-1 can block hepatocyte pyroptosis in nonalcoholic fatty liver disease, indicating that interventions targeting Nrf2 and HO-1 may alleviate hepatocyte pyroptosis (Liu et al., 2024). Here, HMOX1 is linked to metabolic dysfunction-associated steatotic liver disease.